Sun Pharmaceutical Industries Ltd.

•

sunpharma.comBSE: 524715NSE: SUNPHARMA

Market Cap₹ 4,41,958 Cr.

Current Price

High / Low₹ 2,047 / 1,548

Stock P/E36.5

Book Value₹ 360

Price to Book5.05

Dividend Yield0.87 %

ROCE19.1 %

ROE14.8 %

Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company has delivered good profit growth of 38.3% CAGR over last 5 years
Company is almost debt free
Company has consistently been profitable over the last 5 years
Latest quarter profit grew 26.5% YoY, showing strong momentum
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.20x)
Company has been maintaining a healthy dividend payout of 33.4%

CONS

Total debt has risen sharply - up 118.3% year on year
Recurring exceptional / one-off items are inflating headline profit
Stock is trading at 5.0x its book value
Growth is decelerating - 3Y profit CAGR (10.5%) trails the 5Y trend (38.3%)
Expensive relative to growth - PEG of 3.5

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY PHARMA NIFTYLARGEMIDCAP250 NIFTY100 LOWVOL30 NIFTY100 EQL WGT

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	BIOCON	390.95	128.63	63712.89	0.13	136.80	53.36	4336.00	10.89	3.26	19.54

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	11,785	12,003	12,157	11,813	12,525	13,264	13,437	12,816	13,786	14,405	15,469	14,560	15,300
	8,611	9,013	9,028	8,948	9,045	9,481	9,666	9,243	9,779	10,382	10,726	10,658	11,721
Operating Profit	3,174	2,990	3,128	2,866	3,479	3,784	3,770	3,573	4,007	4,023	4,743	3,902	3,579
OPM %	26.93%	24.91%	25.73%	24.26%	27.78%	28.53%	28.06%	27.88%	29.07%	27.93%	30.66%	26.80%	23.39%
	-116	294	305	504	533	482	149	251	-124	900	243	458	928
Interest	81	49	35	74	62	69	52	49	75	100	78	86	100
Depreciation	651	633	622	650	655	626	631	664	701	730	732	775	739
Profit before Tax	2,481	2,791	3,000	2,816	3,424	3,598	3,476	3,254	3,173	4,168	4,227	3,551	4,089
Tax %	18.87%	13.98%	14.41%	5.29%	16.13%	15.77%	16.08%	33.61%	27.43%	24.73%	19.54%	23.30%	29.05%
Net Profit	0	0	0	0	2,861	3,037	2,913	2,154	2,293	3,125	3,381	2,710	2,901
	8.40	9.90	10.50	11.10	11.80	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	31,308	26,416	29,066	32,838	33,498	38,654	43,886	48,497	52,578	58,462	59,734
	21,626	20,881	22,792	25,863	25,030	28,773	32,298	35,748	37,492	41,971	43,486
Operating Profit	9,682	5,535	6,274	6,974	8,468	9,882	11,588	12,749	15,086	16,491	16,248
OPM %	30.93%	20.95%	21.58%	21.24%	25.28%	25.56%	26.40%	26.29%	28.69%	28.21%	27.20%
	1,030	-38	-155	391	-3,447	-3,129	522	1,134	1,473	1,904	2,530
Interest	400	518	555	303	141	127	172	238	231	339	364
Depreciation	1,265	1,500	1,753	2,053	2,080	2,144	2,529	2,557	2,575	2,938	2,976
Profit before Tax	9,048	3,479	3,810	5,010	2,799	4,481	9,408	11,088	13,752	15,119	16,035
Tax %	13.39%	26.19%	15.77%	16.42%	18.39%	24.00%	9.01%	12.98%	20.16%	23.51%	24.15%
Net Profit	7,836	2,568	3,209	4,187	2,285	3,406	8,561	9,648	10,980	11,565	12,163
EPS	29.00	8.70	11.10	15.70	12.10	13.60	35.30	39.91	45.55	47.84	—
Dividend Payout %	12.06%	22.90%	24.75%	25.49%	61.97%	73.31%	32.56%	33.82%	35.13%	33.44%	—

COMPOUNDED SALES GROWTH

10 Years:: 8%
5 Years:: 12%
3 Years:: 10%

COMPOUNDED PROFIT GROWTH

10 Years:: 10%
5 Years:: 32%
3 Years:: 11%

STOCK PRICE CAGR

10 Years:: 9%
5 Years:: 19%
3 Years:: 17%
1 Year:: 14%

RETURN ON EQUITY

10 Years:: 12%
5 Years:: 14%
3 Years:: 16%
Last Year:: 15%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	240	240	240	240	240	240	240	240	240	240
Minority Interest	3,791	3,884	3,314	3,860	3,017	3,055	3,320	3,459	268	310
	36,397	38,074	41,169	45,025	46,223	47,771	55,755	63,427	71,978	83,330
	8,222	9,810	10,468	8,402	4,115	1,601	7,105	3,648	2,621	5,431
Trade Payables	4,395	4,766	4,148	3,584	3,974	4,490	5,682	5,653	6,184	7,334
	5,872	5,335	2,801	3,967	6,542	9,802	5,123	4,969	6,401	8,095
Total Liabilities	58,917	62,109	62,139	65,077	64,110	66,958	77,225	81,396	87,693	1,04,739
	17,675	18,853	21,837	22,847	21,553	22,665	24,065	23,248	22,586	32,822
Capital Work in Progress	1,565	1,434	911	659	937	798	963	1,108	1,234	1,381
	1,192	7,143	7,903	10,143	9,612	12,849	14,824	15,026	18,354	24,723
	6,833	6,881	7,886	7,875	8,997	8,925	10,513	9,868	10,243	11,493
	0	0	0	0	0	0	0	11,249	13,046	15,510
Cash & Bank	15,141	9,929	7,276	6,488	6,446	5,033	5,770	10,521	11,332	11,603
	16,512	17,869	16,328	17,066	16,566	16,688	21,088	10,376	10,898	7,208
Total Assets	58,917	62,109	62,139	65,077	64,110	66,958	77,225	81,396	87,693	1,04,739

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	9,139	4,649	3,083	7,901	7,173	8,015	6,469	12,135	14,072	12,419
Cash from Investing	-4,222	-3,371	-681	-2,589	536	-5,725	-7,944	-690	-5,306	-11,344
Cash from Financing	-2,285	-1,539	-2,731	-5,715	-5,980	-5,193	2,376	-6,710	-7,906	-2,513
	575	-1,003	-1,215	-1,749	726	-1,934	-608	4,735	860	-1,437

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48
	17.23	18.01	18.05	17.96	17.26	16.55	16.12	15.93	14.54
	19.17	18.48	18.43	18.58	19.38	20.12	20.72	21.00	22.06
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	9.02	8.90	8.93	8.87	8.77	8.73	8.58	8.48	8.82

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11

General Updates

2026-09-11 - Intimation under Regulation 30 of SEBI LODR

2026-09-09

General Updates

2026-09-09 - Sun Pharmaceutical Industries Limited has informed the Exchange about Incorporation of a Subsidiary Company

2026-09-08

Credit Rating- New

2026-09-08 - Sun Pharmaceutical Industries Limited has informed the Exchange about International Credit Ratings

2026-09-03

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-03 - Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet

2026-09-01

Press Release

2026-09-01 - Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated September 01, 2026, titled "Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments".

2026-08-26

Copy of Newspaper Publication

2026-08-26 - Newspaper advertisements about Postal Ballot/E-Voting

2026-08-25

Shareholders meeting

2026-08-25 - Notice of Postal Ballot

2026-08-25

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-25 - Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet

2026-08-17

General Updates

2026-08-17 - Update on Lipitor Antitrust Litigation